{"id":13827,"date":"2021-01-27T01:16:21","date_gmt":"2021-01-27T01:16:21","guid":{"rendered":"https:\/\/clinlabint.com\/?p=13827"},"modified":"2021-01-29T01:22:41","modified_gmt":"2021-01-29T01:22:41","slug":"biomedion-buys-compliance-division-of-arivis","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/biomedion-buys-compliance-division-of-arivis\/","title":{"rendered":"BioMedion buys compliance division of arivis"},"content":{"rendered":"
\n

\r\n\"Bio-Rad<\/a>\r\n<\/p>\n<\/div><\/section><\/div>

<\/p>\n<\/div><\/section>
\n

BioMedion buys compliance division of arivis<\/h1>\/ in E-News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\n

BioMedion, a global Compliance Management Software company providing controlled content and raw data management solutions for the life science industry, has acquired the Compliance Division of arivis, a provider of regulatory software and biomedical 3D and big image data software solutions.<\/p>\n

<\/p>\n

Founded in 2000, BioMedion offers a suite of software used in all \u201cgood practice\u201d areas (\u201cGxP\u201d) where quality guidelines and regulations are imperative. The company serves 115 customers in 15 countries around the world.<\/p>\n

The acquisition includes the cloud-based arivis5D content platform that offers a holistic, integrated, and computerized approach for users in the pharmaceutical, medical device, food, and crop sciences industry. With the integration of both parties\u2019 technologies, BioMedion will provide a new operating system for regulated applications operating effectively on one platform in controlled environments.<\/p>\n

Following the acquisition, the arivis5D content platform will be rebranded to neuronOS. neuronOS will reinforce the company\u2019s GxP quality, compliance, and archiving solutions by adding new technology to handle all types of digital content, including instrument data, such as scientific images, and digital forms.<\/p>\n

\u201cWe are excited to announce the acquisition of the Compliance Division of arivis as we take a major step forward in strengthening our compliance competencies and market position not only in Europe, but also in North America and Asia,\u201d said Klaus Pflum, Chairman of the BioMedion\u2019s Supervisory Board.<\/p>\n

Financial details of the transaction were not disclosed.<\/p>\n<\/div><\/section>
\n